ACTICOR BIOTECH: Report of the Combined General Meeting of May 12, 2023
17 Mayo 2023 - 11:05AM
Business Wire
Regulatory News:
ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage
biotechnology company focused on the development of innovative
drugs for the treatment of cardiovascular emergencies, in
particular stroke, today released the report of its Combined
General Meeting held on May 12, 2023
The shareholders attending the meeting, represented by proxy or
voting by post held 10,638,244 votes, representing a quorum of
86.5%.
All resolutions of this Combined General Meeting were adopted,
with the exception of the 23rd and 24th resolutions, as recommended
by the Board of Directors.
Gilles AVENARD, Chief Executive Officer and founder of
Acticor Biotech, said: "The shareholders' meeting was an
opportunity for us to review our clinical successes for the year
2022 and our financial situation, as well as to present our outlook
for the coming years. Following the positive results of the Phase
1b/2a clinical trial, we are fully in line with our strategy to
continue the development of glenzocimab with a view to registering
it for the treatment of cardiovascular emergencies, particularly
stroke. With the successful completion of the €12.2 million
fundraising in March 2023, we cover our financing needs for
operational activities until the end of 2023. In addition to this
transaction, we are currently exploring the best options for
additional financing, including access to the capital markets, to
strengthen our financial resources beyond the end of 2023. The
objective is to cover our financing needs for the year 2024, which
includes the second futility analysis of the ACTISAVE Phase 3
clinical trial in stroke. We will choose the most appropriate
solution and timing in light of the market situation, and of course
in the interest of our shareholders. However, we cannot guarantee
if or when such a transaction will take place or whether it will be
done on satisfactory terms. "
The report of the General Meeting will be available within the
legal deadlines on Acticor Biotech's website, in the
Investors/Shareholders’ Meeting section.
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a
spin-off from INSERM (the French National Institute of Health and
Medical Research), which is aiming to develop an innovative
treatment for cardiovascular emergencies, including ischemic
stroke.
In May 2022, Acticor Biotech presented positive results from its
Phase 1b/2a study, ACTIMIS, at the ESOC, confirming the safety
profile and showing a reduction in mortality and intracerebral
hemorrhage in the glenzocimab-treated group in patients with
stroke. The efficacy of glenzocimab is now being evaluated in an
international Phase 2/3 study, ACTISAVE, which will include 1,000
patients. In July 2022, Acticor Biotech was granted "PRIME" status
by the European Medicines Agency (EMA) for glenzocimab in the
treatment of stroke. This designation will allow the company to
strengthen its interactions and obtain early dialogues with
regulatory authorities.
Acticor Biotech is supported by a panel of European and
international investors (Mediolanum farmaceutici, Karista, Go
Capital, Newton Biocapital, CMS Medical Venture Investment (HK)
Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation).
Acticor Biotech is listed on Euronext Growth Paris since November
2021 (ISIN: FR0014005OJ5 – ALACT).
For more information, visit: www.acticor-biotech.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230517005676/en/
ACTICOR BIOTECH Gilles AVENARD, MD General Manager and
founder gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38
13
Sophie BINAY, PhD Chief Operating Officer and Scientific
Director Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38
13
NewCap Mathilde BOHIN / Quentin MASSÉ Investor Relations
acticor@newcap.eu T. : +33 (0)1 44 71 94 95
NewCap Arthur ROUILLÉ Media Relations acticor@newcap.eu
T. : +33 (0)1 44 71 00 15
Acticor Biotech (EU:ALACT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Acticor Biotech (EU:ALACT)
Gráfica de Acción Histórica
De May 2023 a May 2024